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Introduction
Osteomalacia is a condition characterised by failure of bone 
mineralisation. While abnormalities of vitamin D supply, metabolism 
or action are the most common and well-known causes, chronic 
phosphate deficiency, due to either insufficient input (intake or 
absorption) or renal losses are also important causes of rickets or 
osteomalacia.1 Hypophosphataemia also commonly co-exists with 
vitamin D deficiency, pursuant to secondary hyperparathyroidism. 
Other causes include chronic calcium deficiency, hypophosphatasia, 
fluoride and aluminium excess. 
In respect of chronic hypophosphataemia-associated rickets/
osteomalacia, the commonest aetiology is X-linked dominant 
hypophosphataemia, XLH, (1:20000 births).1 Others include Fanconi 
syndrome, autosomal dominant hypophosphataemic rickets (ADHR) 
and tumour-induced osteomalacia (TIO).2
Case report
A 47-year-old well-nourished black female patient presented to 
Chris Hani Baragwanath Hospital with acute infective bronchitis and 
hypertension. She also complained of left hip pain, severe bilateral 
progressive leg weakness and was noted to have a waddling gait. 
Family history was non-contributory.
Investigation of the muscle weakness identified hypophosphataemia 
of 0.58 mmol/L (reference range [RR] 0.8–1.4 mmol/L), but normal 
serum calcium and renal function. PTH was 62 pmol/L (RR 12–
72), and vitamin D levels were normal. Alkaline phosphatase was 
markedly elevated at 431IU/L (RR 40–120). Muscle enzymes were 
normal. Her TRP (tubular reabsorption of phosphate) was 0.58 (RR > 
0.8). Glycosuria was absent. 
Hip X-rays demonstrated pseudofractures (Figure 1). There was 
no history of malabsorption, antacid use, or family history of either 
osteomalacia or rickets. A diagnosis of tumour-induced osteomalacia 
was considered. The FGF-23 (fibroblast growth factor 23) level was 
less than 2RU/ml (RR 18–108). 
She was treated with oral phosphate replacement and 1-α 
hydroxyvitamin D, 1µg daily. After three months of therapy, her 
phosphate level had risen to 0.97 mmol/L and muscle strength had 
improved somewhat. An 111In-pentetreotide scan, 18 months later, 
demonstrated a small, abnormal area of uptake behind the right knee 
(Figure 2). At surgery, a benign mesenchymal tumour was excised, the 
histology displaying nests of mesenchymal cells with cartilaginous 
differentiation (Figures 3 and 4). The phosphate replacement and 
1-alpha hydroxyvitamin D therapy were subsequently discontinued 
and she has continued to maintain normal serum phosphate levels. 
In addition, resolution (remineralisation) of the pseudofractures 
(Looser zones) has occurred.
Discussion
Our patient manifested severe hypophosphataemia and compatible 
clinical features. Her family history was negative for rickets and 
osteomalacia and her vitamin D status was normal. XLH is the 
commonest cause of hypophosphataemic rickets and typically has 
a childhood onset, although a rarer, milder form may manifest only 
during adulthood.1 TIO, by contrast, is a paraneoplastic condition 
that usually, but not always, presents in adulthood, with the peak 
incidence being in the fifth decade.2 Although initially described in 
1947, the paraneoplastic nature of the condition was first recognised 
by Prader and colleagues in 1959.3 The diagnosis of TIO requires a 
high level of awareness. The tumours are characteristically small. 
Over 80 percent of the tumours are of mesenchymal cell origin and 
usually small and difficult to detect.1,4 This may be facilitated by 
imaging techniques, notably ¹¹¹In-pentetreotide scanning, by virtue 
of the fact that most express somatostatin receptors on their cellular 
plasma membranes.1,5,6 Even so, many remain elusive to detection. 
Most (45 percent) have been located in the lower extremities, as 
was this patient’s tumour. Other common sites are the thorax and 
nasopharynx.4
The hypophosphataemia of TIO results from impaired phosphate 
reabsorption by the proximal renal tubule, due to inhibition and/or 
down-regulation of the type 2 Na-phosphate cotransporter (NPT2a), 
which resides in the brush border membrane.7,8 This inhibition is 
mediated by one or more phosphatonins, a group of hormones which 
have been identified to promote phosphaturia. The commonest and 
best studied of these is FGF-23 (fibroblast growth factor 23) which 
is over-expressed in the majority of tumours that cause TIO and 
identified as the causative hormone in 2001.9 FGF-23 levels, when 
measured by a sensitive assay, are elevated in up to 86 percent of 
cases.10 FGF-23, largely produced by bone-forming cells, osteoblasts 
and osteocytes, plays a physiological role in regulating phosphate 
reabsorption by influencing NPT2a function, as do parathyroid 
 Peer reviewed. (Submitted: 2009-11-02, Accepted: 2009-11-03) JEMDSA 2009;14(3):143-144
144
Case Report:  Tumour-induced osteomalacia: a curable condition
2009 Volume 14 No 3JEMDSA
hormone (PTH) and calcium.8 However, unlike PTH, which increases 
1-alpha hydroxylase mRNA expression and activity, FGF-23 has 
an inhibitory effect on the conversion of 25-hydroxyvitamin D to 
1,25-dihydroxyvitamin D.
FGF-23 excess is accountable for the phosphaturia of XLH, ADHR 
and most cases of TIO, but the reasons for this differ among these 
conditions.11 FGF-23 is normally cleaved by an endopeptidase, 
encoded for by the PHEX gene (the phosphate regulating gene with 
homologies to endopeptidase on the X-chromosome), mapped to 
Xp22.1.
i In the rare condition of ADHR, the gene encoding FGF-23 has 
undergone a missense mutation which renders the gene 
product(FGF-23) refractory to proteolysis by PHEX, resulting in 
abnormally high FGF-23 levels.
ii In XLH, FGF-23 structure is normal. The defect resides in 
the PHEX gene, on the X-chromosome, which undergoes an 
inactivating mutation, of which approximately 140 have now 
been documented. Cleavage of FGF-23, by the deficient or 
abnormal endopeptidase, is thus impaired and accounts for the 
high circulating concentration of FGF-23.11
iii In TIO, tumour FGF-23 mRNA and the secreted FGF-23 are 
overexpressed in most instances.11 However, as in the patient 
reported here, the FGF-23 levels may not be elevated. Indeed, 
in this instance they were below the normal physiological range. 
Detection of an elevated FGF-23 is affected by the sensitivity of 
the assay employed, but it is most likely that her tumour was 
secreting one of a number of the other phosphatonins which 
circulate normally and which also have been associated with TIO. 
These include MEPE-ASARM-protein, sFRP4, and FGF-7.1,5,8,10
The sentinel importance of recognising this rare condition is that, as 
in our patient, it is curable by resection of the tumour. The alternative, 
unfortunately, is lifelong therapy with oral phosphate and calcitriol 
replacement, for which, owing to unpleasant gastrointestinal side-
effects, compliance is often sub-optimal. Since these tumours often 
express somatostatin receptors on their cell membranes, some 
success may be achieved by somatostatin analogue therapy, but this 
is by no means universal.6
Conclusion 
Tumour-induced osteomalacia is a paraneoplastic condition which is 
rare but curable. It is usually caused by overexpression of FGF-23 by 
the tumour. In our patient, however, FGF-23 levels were low and the 
osteomalacia consequently attributable to one of the other less well 
studied phosphatonins.
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Figure 1: Hip X-ray of the patient demonstrating a pseudofracture in the metaphyses  
of the femur
Figure 2: A negative field recovery CT image of the pentetreotide scan demonstrating a 
mass behind the right knee (see arrows)
Figure 3: Macroscopic appearance of the tumour containing cartilaginous areas
Figure 4: Histology demonstrating nests of mesenchymal cells with cartilaginous 
differentiation
